 |
|
Effect of Isoniazid Chemoprophylaxis on HIV-Related Mycobacterial Disease
Neil M. H. Graham, MBBS, MD;
Noya Galai, PhD;
Kenrad E. Nelson, MD;
Jacqueline Astemborski, MHS;
Margaret Bonds, RN;
Rosetta T. Rizzo, MMS;
Laura Sheeley, MSN;
David Vlahov, PhD
Arch Intern Med. 1996;156(8):889-894.
Abstract
| |
Objectives
The aims of this study were to (1) identify trends and risk factors for mycobacterial disease and (2) determine the effect of expanded access to isoniazid chemoprophylaxis on tuberculosis incidence.
Methods
A prospective observational cohort study was conducted among community-based injecting drug users (IDUs); 2960 IDUs (942 human immunodeficiency virus [HIV] seropositive) were followed up from January 1988 to June 1994. Directly observed chemoprophylaxis with twice-weekly isoniazid (10 to 15 mg/kg) was offered to purified protein derivative (PPD) tuberculinpositive induration diameter in HIVseropositive subjects and diameter in HIVseronegative subjects) individuals but not to those with cutaneous anergy. Overall and annual incidence rates of disease due Mycobacterium tuberculosis, Mycobacterium avium complex, and other atypical mycobacteria were estimated using Poisson regression.
Results
HIV seropositivity was the strongest risk factor for tuberculosis, M avium complex, and other mycobacterial disease (relative risk [RR], 3.8, 17.2, and 6.9, respectively). Median CD4 lymphocyte cell counts for the three groups of mycobacterial disease were 0.17, 0.03, and 0.02 X 109/L and within 6 months of diagnosis (before or after). Overall incidence rates of tuberculosis, M avium complex disease, and other mycobacterial disease were 1.9,8.8, and 2.7 per 1000 person-years, respectively. Tuberculosis incidence peaked in 1991 at six per 1000 person-years. However, after access to directly observed preventive therapy was expanded for tuberculin-positive subjects, incidence fell to only one case in 1992 and zero cases for 24 months from mid-1992 to mid-1994. During this period the number of PPD-positive patients who completed at least 26 weeks of therapy (or were still receiving isoniazid) more than tripled (from 21 to 70). None of the 12 patients with tuberculosis diagnosed during follow-up had received any preventive therapy. In addition, no tuberculosis developed among participants with cutaneous anergy. Calendar trends in risk for M avium complex and tuberculosis diverged after expanded access to isoniazed prophylaxis. Compared with 1988-1989, risk of M avium complex increased sevenfold. Tuberculosis risk fell 83% from the peak risk in 1990-1991.
Conclusions
Expanded to directly observed isoniazid therapy apy for t tuberculin-positive IDUs with and without HIV infection was associated with an 83% drop in tuberculosis incidence while the same period M avium complex i complex incidence significantly increased. These population-based data are consistent with those obtained from clinical trials of isoniazid prophylaxis and were obtained without offering chemoprophylaxis to HIV-infected patients with cutaneous anergy.
(Arch Intern Med. 1996;156:889-894)
Author Affiliations
From the Departments of Epidemiology (Drs Graham, Galai, Nelson, and Vlahov and Mss Astemborski, Bonds, and Sheeley) and Medicine (Drs Graham, Nelson, and Vlahov), The Johns Hopkins University School of Hygiene and Public Health, Baltimore, Md, and the Baltimore City Department of Health (Ms Rizzo).
 CiteULike  Connotea  Del.icio.us  Digg  Reddit  Technorati  Twitter
What's this?
THIS ARTICLE HAS BEEN CITED BY OTHER ARTICLES
|
Trends in Tuberculosis/Human Immunodeficiency Virus Comorbidity, United States, 1993-2004
Albalak et al.
Arch Intern Med 2007;167:2443-2452.
ABSTRACT
| FULL TEXT
Beneficial and perverse effects of isoniazid preventive therapy for latent tuberculosis infection in HIV-tuberculosis coinfected populations
Cohen et al.
Proc. Natl. Acad. Sci. USA 2006;103:7042-7047.
ABSTRACT
| FULL TEXT
In Vitro Antimycobacterial Activities of 2'-Monosubstituted Isonicotinohydrazides and Their Cyanoborane Adducts
Maccari et al.
Antimicrob. Agents Chemother. 2002;46:294-299.
ABSTRACT
| FULL TEXT
Tuberculosis in the Homeless . A Prospective Study
MOSS et al.
Am. J. Respir. Crit. Care Med. 2000;162:460-464.
ABSTRACT
| FULL TEXT
Prophylaxis against Opportunistic Infections in Patients with Human Immunodeficiency Virus Infection
Kovacs and Masur
NEJM 2000;342:1416-1429.
FULL TEXT
Tuberculosis prophylaxis for the chronically dialysed patient--yes or no?
Korzets and Gafter
Nephrol Dial Transplant 1999;14:2857-2859.
FULL TEXT
A Tuberculin Screening and Isoniazid Preventive Therapy Program in an Inner-City Population
BOCK et al.
Am. J. Respir. Crit. Care Med. 1999;159:295-300.
ABSTRACT
| FULL TEXT
Preventive Therapy for Tuberculosis in HIV-Infected Persons: Analysis of Policy Options Based on Tuberculin Status and CD4+Cell Count
Sawert et al.
Arch Intern Med 1998;158:2112-2121.
ABSTRACT
| FULL TEXT
A Trial of Three Regimens to Prevent Tuberculosis in Ugandan Adults Infected with the Human Immunodeficiency Virus
Whalen et al.
NEJM 1997;337:801-808.
ABSTRACT
| FULL TEXT
Tuberculous Pericarditis in a Woman Infected With Human Immunodeficiency Virus Type 1, Long-term Nonprogressive
Buil et al.
Arch Intern Med 1997;157:1391-1392.
ABSTRACT
Incidence of Tuberculosis in Injection Drug Users in San Francisco . Impact of Anergy
DALEY et al.
Am. J. Respir. Crit. Care Med. 1997;157:19-22.
ABSTRACT
| FULL TEXT
|
